NCT03494569View on ClinicalTrials.gov

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 6, 2018

Primary Completion Date

October 11, 2025

Study Completion Date

October 11, 2025

Conditions
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Myeloid LeukemiaAcute Myeloid Leukemia in RemissionHematopoietic Cell Transplantation RecipientMinimal Residual DiseaseMyelodysplastic SyndromeSecondary Acute Myeloid Leukemia
Interventions
DRUG

Fludarabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given as per City of Hope Standard Operating Procedure

RADIATION

Total Marrow Irradiation

Undergo TMLI

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER